Physician profile

David Franklin Snipelisky

Advanced Heart Failure and Transplant Cardiology · Weston, FL

NPI 1699069088

$250,466.25

in general payments reported to CMS, 2019-2025

32 companies · $61K in 2025

The $61K reported for 2025 was more than what 95% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$75,368.81
Honoraria$33,800.00
Travel and Lodging$25,261.10
Consulting Fee$12,100.00
Food and Beverage$11,238.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $171,091.51 2019-2025
Impulse Dynamics (USA) INC. $62,465.88 2022-2025 Optimizer, Optimizer
Abbott Laboratories $6,653.06 2019-2025 Cardiomems, Mitraclip
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $2,123.52 2023 Lifevest
Novartis Pharmaceuticals Corporation $1,323.01 2019-2024 Leqvio
Abiomed $1,201.95 2019-2022
Alexion Pharmaceuticals, INC. $1,095.02 2024
Medtronic, INC. $599.31 2023-2025 Azure Xt Dr Mri Surescan, Hvad Pump Implant Kit, Micra
Boston Scientific Corporation $493.21 2019-2025 Watchman Flx, Watchman Access System, Sentinel
Biosense Webster, INC. $459.00 2024-2025 Carto 3
Boehringer Ingelheim Pharmaceuticals, INC. $412.54 2020-2025 Jardiance
Cvrx, INC. $316.01 2021-2024 Barostim Neo System
Janssen Pharmaceuticals, INC $306.55 2019-2024 Xarelto
E.R. Squibb & Sons, L.L.C. $261.49 2019-2025 Camzyos
Medtronic Vascular, INC. $258.50 2019-2020
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $225.47 2019-2023 Farxiga
Vifor Pharma, INC. $214.58 2019
Amgen INC. $202.00 2019-2025 Repatha, Repatha
Alnylam Pharmaceuticals INC. $143.14 2019-2023 Onpattro
Cardiva Medical, INC. $126.47 2022-2023 Cardiva Vascade Mvp Vvcs 6-12f
Bridgebio Pharma, INC. $95.95 2025 Attruby
Cordis US Corp. $86.96 2025 Mynx Control Venous
Endotronix, INC. $82.60 2025 Cordella Pulomonary Artery Pressure Sensor
Kiniksa Pharmaceuticals International, Plc $39.47 2024 Arcalyst
Procyrion, INC. $34.60 2022
W. L. Gore & Associates, INC. $32.52 2021
Heartflow, INC. $29.84 2025
Amarin Pharma, INC. $23.88 2019
Scpharmaceuticals INC. $19.17 2023
Atricure, INC. $17.60 2024
Chiesi USA, INC. $16.12 2022
Novo Nordisk INC $15.32 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David Franklin Snipelisky

$250,466.25

in general payments reported 2019-2025

Years
2019-2025
Top company
Pfizer INC.
Context
The $61K reported for 2025 was more than what 95% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).

https://glasscript.com/doctor/212924/david-franklin-snipelisky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.